Log in
Enquire now
‌

US Patent 12077790 Optimized binuclease fusions and methods

Patent 12077790 was granted and assigned to Resolve Therapeutics on September, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
Resolve Therapeutics
Resolve Therapeutics
0
Date Filed
December 23, 2021
0
Date of Patent
September 3, 2024
0
Patent Applicant
Resolve Therapeutics
Resolve Therapeutics
0
Patent Application Number
17560522
0
Patent Citations
‌
US Patent 7087726 Anti-interferon-α antibodies
0
‌
US Patent 7098016 Ribonuclease zymogen design
0
‌
US Patent 7118751 DNA vaccines encoding antigen linked to a domain that binds CD40
0
‌
US Patent 7176278 Modified transferrin fusion proteins
0
‌
US Patent 7247302 Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
0
‌
US Patent 7317091 Optimized Fc variants
0
‌
US Patent 7364731 Polypeptide variants
0
‌
US Patent 7407785 Human DNase I hyperactive variants
0
‌
US Patent 7416875 Cytotoxic ribonuclease variants
0
‌
US Patent 7442527 Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
0
•••
Patent Inventor Names
James Arthur Posada
0
Chris Gabel
0
Weihong Yu
0
Sanjay Patel
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
12077790
0
Patent Primary Examiner
‌
Phuong Huynh
0

Find more entities like US Patent 12077790 Optimized binuclease fusions and methods

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo